|Articles|July 22, 2010

Regulatory Roundup: ICH Draft Residual Solvents Guideline Published; And More.

ICH Draft Residual Solvents Guideline Published; And More.

FDA published this week as a draft recommendation the Step-2 version of the International Conference on Harmonization’s Q3C(R5) Guideline on Residual Solvents to account for new toxicity data related to cumene (Cumol; isopropylbenzene; isopropylbenzol; (1-methyl/ethyl)benzene; 2­Phenylpropane). ICH finalized and approved Q3C(R4), the fourth revision to this guideline, in July 2007. This Step-2 guideline represents a fifth revision, which ICH issued in the form of a final concept paper in June 2009 and approved in March 2010. In Q3C(R4), cumene is listed as a Class-3 solvent in ICH's table of residual solvents. The fifth revision aims to place cumene into Class 2 based on new toxicity data.

 

The Bulk Pharmaceuticals Task Force (BPTF), an affiliate of the Society of Chemical Manufacturers and Affiliates (SOCMA), has released a Quality Agreement template designed for the custom manufacture and release of active pharmaceutical ingredients (APIs). The organization released a general API Quality Agreement Template in May 2010. The templates are meant to help manufacturers, suppliers, and distributors comply with current regulations, including the International Conference on Harmonization Q7 guideline, by putting into place standardized quality agreements.


Related to this article

PharmTech Weekly Roundup—October 2, 2026
This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
Regulatory Roundup—September 2026
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.